Bebetter Med - Crunchbase Company Profile & Funding

Q: Where is Bebetter Med's headquarters?

Bebetter Med is located in Guangzhou, Guangdong, China.

Q: Who invested in Bebetter Med?

Bebetter Med has 4 investors including Yingke Capital And Gaoxin Capital.

Q: When was the last funding round for Bebetter Med?

Bebetter Med closed its last funding round on obfuscated from a Private Equity round.

Q: How much funding has Bebetter Med raised to date?

Bebetter Med has raised obfuscated.

Overview

Bebetter Med

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

See more interactive data and historical milestones on desktop for the best experience

About Bebetter Med

CB Rank

82218

Bebetter Med operates as a pharmaceutical research and development enterprise with a focus on small molecule oncology drugs.

Founded

obfuscation

Public

Private Equity

Guangzhou, Guangdong, China

51-100

www.bebettermed.cn/

Health Care

Medical

Oncology

Pharmaceutical

Funding Rounds

Private Equity

OBF

obfuscation

Venture - Series Unknown

OBF

obfuscation

Details

Legal Name

Guangzhou Bibet Pharmaceutical Co., Ltd.

Also Known As

必贝特医药, Bibbet

Operating Status

Active

Stock Symbol

SSE:688759

Company Type

For Profit

About the Company

Bebetter Med operates as a pharmaceutical research and development enterprise with a focus on small molecule oncology drugs.

Phone Number

020-36657255

Contact Email

info@bebettermed.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

BEBT-908

A first-in-class PI3K/HDAC dual-target inhibitor for treating relapsed or refractory diffuse large B-cell lymphoma and other cancers.

BEBT-209

An investigational drug for treating metastatic triple-negative breast cancer in clinical trials.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Private Equity Round - Bebetter Med	2	obfuscated obfuscation	Yingke Capital	Private Equity
obfuscated obfuscation	Private Equity Round - Bebetter Med	2	obfuscated obfuscation	Yingke Capital	Private Equity
obfuscated obfuscation	Private Equity Round - Bebetter Med	2	obfuscated obfuscation	Yingke Capital	Private Equity
obfuscated obfuscation	Private Equity Round - Bebetter Med	2	obfuscated obfuscation	Yingke Capital	Private Equity
obfuscated obfuscation	Private Equity Round - Bebetter Med	2	obfuscated obfuscation	Yingke Capital	Private Equity

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Private Equity Round - Bebetter Med	2	obfuscated obfuscation	Yingke Capital	Private Equity
obfuscated obfuscation	Private Equity Round - Bebetter Med	2	obfuscated obfuscation	Yingke Capital	Private Equity
obfuscated obfuscation	Private Equity Round - Bebetter Med	2	obfuscated obfuscation	Yingke Capital	Private Equity
obfuscated obfuscation	Private Equity Round - Bebetter Med	2	obfuscated obfuscation	Yingke Capital	Private Equity
obfuscated obfuscation	Private Equity Round - Bebetter Med	2	obfuscated obfuscation	Yingke Capital	Private Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Yingke Capital	Yes	Private Equity Round - Bebetter Med	Mingfei Qian
Yingke Capital	Yes	Private Equity Round - Bebetter Med	Mingfei Qian
Yingke Capital	Yes	Private Equity Round - Bebetter Med	Mingfei Qian
Yingke Capital	Yes	Private Equity Round - Bebetter Med	Mingfei Qian
Yingke Capital	Yes	Private Equity Round - Bebetter Med	Mingfei Qian